These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 22440916)
1. Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Paeshuyse J; Dallmeier K; Neyts J Curr Opin Virol; 2011 Dec; 1(6):590-8. PubMed ID: 22440916 [TBL] [Abstract][Full Text] [Related]
2. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir. Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191 [TBL] [Abstract][Full Text] [Related]
3. New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Asselah T; Marcellin P Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141 [TBL] [Abstract][Full Text] [Related]
4. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Pawlotsky JM Hepatology; 2011 May; 53(5):1742-51. PubMed ID: 21374691 [TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France. Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594 [TBL] [Abstract][Full Text] [Related]
6. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S; N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903 [TBL] [Abstract][Full Text] [Related]
7. Treatment of hepatitis B and C in children. El-Shabrawi M; Hassanin F Minerva Pediatr; 2014 Oct; 66(5):473-89. PubMed ID: 25253190 [TBL] [Abstract][Full Text] [Related]
8. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C. Foote BS; Spooner LM; Belliveau PP Ann Pharmacother; 2011 Sep; 45(9):1085-93. PubMed ID: 21828346 [TBL] [Abstract][Full Text] [Related]
9. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. Reddy KR; Zeuzem S; Zoulim F; Weiland O; Horban A; Stanciu C; Villamil FG; Andreone P; George J; Dammers E; Fu M; Kurland D; Lenz O; Ouwerkerk-Mahadevan S; Verbinnen T; Scott J; Jessner W Lancet Infect Dis; 2015 Jan; 15(1):27-35. PubMed ID: 25482330 [TBL] [Abstract][Full Text] [Related]
10. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1. Manns MP; Markova AA; Calle Serrano B; Cornberg M Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568 [TBL] [Abstract][Full Text] [Related]